Meeting
2014 ASCO Annual Meeting
Evaluation of PI3K-pathway–activation status in matched primary (P) and metastatic (M) ER+/HER2- breast cancer (BC) lesions according to PIK3CA-mutation status.
Authors
Debora Fumagalli
Jules Bordet Institute, Breast Cancer Translational Research Laboratory, Brussels, Belgium
Debora Fumagalli , Vinu Jose , Roberto Salgado , Stefan Michiels , Timothy R. Wilson , Carol O'Brien , Ling Huw , Ghizlane Rouas , Carmen Criscitiello , Lina Pugliano , Martine J. Piccart-Gebhart , Mark R. Lackner , Sherene Loi , Christos Sotiriou
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Genomic and Epigenomic Biomarkers
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 11060)
DOI
10.1200/jco.2014.32.15_suppl.11060
Abstract #
11060
Poster Bd #
342
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Evaluation of pathologic and genomic characteristics in male breast cancer (MBC) patients.
First Author: Damien Mikael Hansra
Poster
2019 ASCO Annual Meeting
Next-generation sequencing (NGS) results among hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC) patients treated with a CDK4 & 6 inhibitor: A retrospective observational study based on real‑world data.
First Author: Erika Paige Hamilton
Poster
2016 ASCO Annual Meeting
A cancer precision medicine platform for multiple simultaneous genomic assays from metastatic biopsies (bx) in ER+ metastatic breast cancer.
First Author: Nikhil Wagle
Poster
2023 ASCO Annual Meeting
A phase 1b/2 dose escalation and expansion study of OP-1250 in combination with ribociclib or alpelisib in patients with advanced and/or metastatic estrogen receptor–positive (ER+)/HER2-negative (HER2-) breast cancer.
First Author: Virginia F. Borges